Journal Article Summary
The article investigates a new formulation of esomeprazole, called Esomezol DR, which is designed to provide extended gastric acid suppression compared to the traditional enteric-coated formulation (Nexium). This research is significant because many patients experience nocturnal acid breakthrough, where stomach acid continues to be produced during the night, leading to discomfort and potential damage to the esophagus. By developing a dual delayed-release formulation, the study aims to improve the management of acid-related disorders, particularly gastroesophageal reflux disease (GERD), which is prevalent and can severely affect quality of life.
The study involved healthy male participants who were given either the new DR formulation or the conventional EC formulation in a randomized, crossover design. Each participant received both formulations over two separate periods, with a washout phase in between. The results showed that the DR formulation maintained a more stable plasma concentration of esomeprazole and demonstrated a tendency for better gastric acid suppression during nighttime hours compared to the EC formulation. While both formulations provided similar overall systemic exposure, the DR formulation showed promise in reducing nocturnal acid production, which could benefit patients suffering from nighttime GERD symptoms.
However, the study has limitations, including its focus solely on healthy male subjects, which may not represent the broader population of GERD patients, including women and those with other health conditions. Additionally, while the findings suggest potential benefits of the DR formulation, patients should consult their healthcare professionals before making any changes to their treatment plans. Discussing individual symptoms and treatment options is crucial, especially for those experiencing persistent acid-related issues, as the new formulation may not be suitable for everyone.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Kim Hyun Chul, Yang Eunsol, Ban Mu Seong, Kim Yu Kyong, Hong Sung Hee, Jung Jina, Jang In-Jin, Lee SeungHwan. Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects. Drug Design, Development and Therapy 2023. DOI: 10.2147/DDDT.S392533. PMID: 37077412. PMCID: PMC10106809.
Featured Pill Pals Product
Omeprazole 20 mg Capsules --- 30 Count --- Generic for Prilosec --- Xiromed Pharma
Omeprazole 20 mg Capsules — 30 Count — Generic for Prilosec — Xiromed Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
